First Myeloma Patient in Study Treated with New CAR T-Cell Therapy bb21217
The first patient with relapsed/refractory multiple myeloma has been treated with the investigational therapy bb21217, according to the clinical-stage company bluebird bio. The treatment candidate bb21217, developed under a joint collaboration of bluebird bio and Celgene, is being tested in the two-part open-label Phase 1 CRB-402 study (NCT03274219),…